A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis |
Type de publication | Journal Article |
Year of Publication | 2014 |
Auteurs | Aires V, Brassart B, Carlier A, Scagliarini A, Mandard S, Limagne E, Solary E, Martiny L, Tarpin M, Delmas D |
Journal | MOLECULAR NUTRITION & FOOD RESEARCH |
Volume | 58 |
Pagination | 1785-1794 |
Date Published | SEP |
Type of Article | Article |
ISSN | 1613-4125 |
Mots-clés | Apoptosis, Cell proliferation, colon cancer, Polyphenols, PPAR, resveratrol |
Résumé | Scope: Resveratrol may function as a chemopreventive agent. A recent clinical study demonstrates a reduction in tumor cell proliferation in colorectal patients receiving repeated oral ingestion of resveratrol. However, gaps remain in our knowledge of the molecular mechanisms by which resveratrol exerts its chemopreventive effect. We have previously demonstrated that resveratrol induces apoptosis in colon cancer cells and that resveratrol can sensitize chemoresistant colon cancer cells to various drugs. Based on its ability to activate peroxisome proliferator-activated receptor gamma (PPAR gamma) in colon cancer cells, we sought to determine the implication of this nuclear transcription factor in resveratrol-induced apoptosis. Methods and results: Transient transfection of cancer cells with a dominant-negative PPAR gamma mutant or treatment with a PPAR gamma antagonist (GW9662) reversed the inhibitory effect of resveratrol. Moreover, GW9662 prevented disruption of the cell cycle induced by resveratrol and consequently abrogated resveratrol-induced apoptosis. Tumor cell death was potentiated by combining resveratrol with rosiglitazone, a PPAR gamma agonist. Conclusion: The results show that PPAR gamma plays a role in resveratrol-induced apoptosis of colon carcinoma cells. The combination of resveratrol with a PPAR gamma agonist could be a promising pharmacological approach for treatment of colorectal cancer. |
DOI | 10.1002/mnfr.201300962 |